In patients with T2D combined with arteriosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk, GLP-1 RAs have been recommended as one of the preferred combined medications. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.